Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?

Full text
Costa, Luis H. A. [1] ; Santos, Bruna M. [1] ; Branco, Luiz G. S. [1]
Total Authors: 3
[1] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Basic & Oral Biol, BR-14040904 Ribeirao Preto - Brazil
Total Affiliations: 1
Document type: Journal article
Source: European Journal of Pharmacology; v. 889, DEC 15 2020.
Web of Science Citations: 3

The absence of a specific treatment for SARS-CoV-2 infection led to an intense global effort in order to find new therapeutic interventions and improve patient outcomes. One important feature of COVID-19 pathophysiology is the activation of immune cells, with consequent massive production and release of inflammatory mediators that may cause impairment of several organ functions, including the brain. In addition to its classical role as a neurotransmitter, serotonin (5-hydroxytryptamine, 5-HT) has immunomodulatory properties, downregulating the inflammatory response by central and peripheral mechanisms. In this review, we describe the roles of 5-HT in the regulation of systemic inflammation and the potential benefits of the use of specific serotonin reuptake inhibitors as a coadjutant therapy to attenuate neurological complications of COVID-19. (AU)

FAPESP's process: 19/27231-9 - Effect of fluvoxamine on neuroimmune alterations in septic rats
Grantee:Luís Henrique Angenendt da Costa
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 16/17681-9 - Pathophysiological changes during systemic inflammation
Grantee:Luiz Guilherme de Siqueira Branco
Support Opportunities: Research Projects - Thematic Grants